In its simplest form, decentralisation means that no single power has exclusive control over the data or its processing. In the context of blockchain, this is achieved because the data is also distributed, ie, it is stored at each individual node in the network and not a single location. In terms of clinical trials, decentralisation means that it is not happening at a single central site; instead, it may be a multi-centre trial or be using connected technologies to enable participants and investigators to report remotely – while remaining within the overall structure of scientific and regulatory controls.
NFTs’ main value proposition is that by creating a unique, blockchain-backed record of each unit of creative work, they can not just encode the sense of its authenticity and scarcity but also enable artists to lay down and enforce the rules around copyright transfer, usage and monetization. G-J van Rooyen, co-founder of blockchain content protection firm Custos Media Technologies, commented to Cointelegraph:
“First, NFTs allow us to securely trace the transfer of rights — in the same way as a Bitcoin payment securely traces the transfer of funds. Second, NFTs can provide perpetual support to creators. For example, an NFT could specify that creators should be rewarded each time an asset is resold at a higher value.”